Further Benefit the Majority of Patients, Make Positive Impact on the Operation Results of the Group
The anticoagulant drug “fondaparinux sodium injection” (strength: 0.5ml: 2.5mg) developed by the Group has been granted with drug registration approval for manufacture by the National Medical Products Administration of the People’s Republic of China and is deemed to have passed the quality and efficacy consistency evaluation of generic drugs.
Fondaparinux sodium injection is indicated for the prevention of venous thromboembolic events in patients undergoing major orthopedic surgeries of the lower limbs, such as hip fracture surgery, major knee surgery or hip replacement surgery; for the treatment of patients with unstable angina or non-ST-segment elevation myocardial infarction (UA/NSTEMI) receiving emergency (<120 mins) percutaneous coronary intervention (PCI) without indications; for the treatment of patients with ST-segment elevation myocardial infarction who are using thrombolytics or who initially did not receive other forms of reperfusion therapy. Fondaparinux sodium injection is included in the 2021 edition of the National Reimbursement Drug List (Class B). The obtaining of drug registration approval in relation to the Product is expected to be beneficial to the future market sales and market competition of the Product, as well as further benefit the majority of patients and make positive impact on the operation results of the Group.
Dr. Che Fengsheng, Chairman and Executive Director of the Group said: " Adhering to the overall strategic goal for the full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses, the Group endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China. The approval of the production of the anticoagulant drug sulforaphane sodium injection will further bring convenience to patients and will advance the Group's business development.”